Bicara Therapeutics Inc. (BCAX) stock
BCAXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Nov 9, 2026Score 8/30
$9.75−0.27 (-2.69%)
Close on Nov 16, 2026Market cap $645.19MP/E –Yield –
Bicara Therapeutics EPS
Diluted earnings per share is net income divided by the share count including options and convertible securities.
For fiscal 2025 it was -$2.52.
Annual eps
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$2.52 | – |
| FY2024 | Dec 31, 2024 | -$4.05 | – |
| FY2023 | Dec 31, 2023 | -$89.61 | – |
Quarterly eps
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -$1.04 | – |
| Q2 FY2026 | Jun 30, 2026 | -$0.82 | – |
| Q1 FY2026 | Mar 31, 2026 | -$0.93 | – |
| Q3 FY2025 | Sep 30, 2025 | -$0.67 | – |
| Q2 FY2025 | Jun 30, 2025 | -$0.50 | – |
| Q1 FY2025 | Mar 31, 2025 | -$0.68 | – |
| Q3 FY2024 | Sep 30, 2024 | -$1.60 | – |
| Q2 FY2024 | Jun 30, 2024 | -$19.01 | – |
| Q1 FY2024 | Mar 31, 2024 | -$18.94 | – |
| Q3 FY2023 | Sep 30, 2023 | -$38.23 | – |
- Revenue
- Gross Profit
- Operating Income
- Net Income
- EBITDA
- Free Cash Flow
- Operating Cash Flow
- R&D Expenses
- Gross Margin
- Operating Margin
- Profit Margin
- Total Debt
- Cash
- Total Assets
- Shares Outstanding
- Market Cap
- Enterprise Value
- PE Ratio
- Price to Sales Ratio
- Price to Book Ratio
- EV/EBITDA
- Price to Free Cash Flow
- All statistics
See a number that looks wrong?